Compounds > finafloxacin
Page last updated: 2024-11-12

finafloxacin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

finafloxacin : A quinolone that is 4-oxo-1,4-dihydroquinoline-3-carboxylic acid which is substituted at positions 1, 6, 7 and 8 by cyclopropyl, fluoro, hexahydropyrrolo[3,4-b][1,4]oxazin-6-yl and cyano groups respectively; an antibiotic used for treatment of acute otitis externa (swimmer's ear) caused by the bacteria Pseudomonas aeruginosa and Staphylococcus aureus. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID11567473
CHEMBL ID1908370
CHEBI ID85176
SCHEMBL ID1002869
MeSH IDM0560479

Synonyms (50)

Synonym
finafloxacin
d26osn9q4r ,
finafloxacin [inn]
(-)-8-cyano-1-cyclopropyl-6-fluoro-7-((4as,7as)-hexahydropyrrolo(3,4-b)-1,4-oxazin-6(2h)-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
209342-40-5
unii-d26osn9q4r
xtoro
chebi:85176 ,
al-60371
CHEMBL1908370
SCHEMBL1002869
8-cyano-1-cyclopropyl-6-fluoro-7-((1s,6s)-2-oxa-5,8-diazabicyclo[4.3.0]non-8-yl)-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid
FYMHQCNFKNMJAV-HOTGVXAUSA-N
finafloxacin [orange book]
finafloxacin [mi]
finafloxacin [who-dd]
8-cyano-1-cyclopropyl-6-fluoro-7-((4as,7as)-hexahydropyrrolo[3,4-b][1,4]oxazin-6(2h)-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
finafloxacin (inn)
xtoro (tn)
D10575
8-cyano-1-cyclopropyl-6-fluoro-7-[(4as,7as)-hexahydropyrrolo[3,4-b][1,4]oxazin-6(2h)-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
bay35-3377
AC-29291
DTXSID10175096 ,
8-cyano-1-cyclopropyl-6-fluoro-7-[(4as,7as)-hexahydropyrrolo[3,4-b][1,4]oxazin-6(2h)-yl]-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid
gastrochinolon
gastroquinolone
DB09047
CS-5557
HY-13451
(-)-8-cyano-1-cyclopropyl-6-fluoro-7-((4as,7as)-hexahydropyrrolo(3,4-b)-1,4-oxazin-6(2h)-yl)-4-oxo-1
AKOS027422437
3-quinolinecarboxylic acid,8-cyano-1-cyclopropyl-6-fluoro-7-[(4as,7as)-hexahydropyrrolo[3,4-b]-1,4-oxazin-6(2h)-yl]-1,4-dihydro-4-oxo-
BCP23882
Q21011229
7-[(4as,7as)-3,4,4a,5,7,7a-hexahydro-2h-pyrrolo[3,4-b][1,4]oxazin-6-yl]-8-cyano-1-cyclopropyl-6-fluoro-4-oxoquinoline-3-carboxylic acid
NCGC00510315-02
al60371
gtpl10809
MS-26731
EN300-18167156
7-[(4as,7as)-octahydropyrrolo[3,4-b][1,4]oxazin-6-yl]-8-cyano-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
8-cyano-1-cyclopropyl-6-fluoro-7-((4as,7as)-hexahydropyrrolo(3,4-b)(1,4)oxazin-6(2h)-yl)-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid
3-quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-7-((4as,7as)-hexahydropyrrolo(3,4-b)-1,4-oxazin-6(2h)-yl)-1,4-dihydro-4-oxo-
8-cyano-1-cyclopropyl-6-fluoro-7-((4as,7as)-hexahydropyrrolo(3,4-b)(1,4)oxazin-6(2h)-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
finafloxacino
8-cyano-1-cyclopropyl-6-fluoro-7-((4as,7as)-hexahydropyrrolo(3,4-b)-1,4-oxazin-6(2h)-yl)-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid
finafloxacine
finafloxacinum
dtxcid5097587

Research Excerpts

Overview

Finafloxacin is a novel fluoroquinolone with improved antimicrobial efficacy, especially in an acidic environment. The drug may find useful applications in infections where the local pH is low.

ExcerptReferenceRelevance
"Finafloxacin is a novel fluoroquinolone exhibiting enhanced activity under acidic conditions and a broad-spectrum antibacterial profile. "( Pharmacokinetics of Intravenous Finafloxacin in Healthy Volunteers.
Chiesa, J; Dalhoff, A; Fischer, C; Fuhr, U; Lückermann, M; Taubert, M, 2017)		2.18
"Finafloxacin is a fluoroquinolone antimicrobial agent that exhibits optimum efficacy in slightly acidic environments. "( Finafloxacin: first global approval.
McKeage, K, 2015)		3.3
"Finafloxacin is a new generation fluoroquinolone with interesting preclinical characteristics and pH-related efficacy."( Finafloxacin for the treatment of urinary tract infections.
Bartoletti, R; Bjerklund Johansen, TE; Cai, T; M E Wagenlehner, F; Perletti, G, 2015)		2.58
"Finafloxacin is a novel fluoroquinolone with improved antimicrobial efficacy, especially in an acidic environment. "( High Efficacy of Finafloxacin on Helicobacter pylori Isolates at pH 5.0 Compared with That of Other Fluoroquinolones.
Jung, HC; Kim, JM; Kim, JS; Kim, N; Lee, DH; Lee, JW; Lee, SM; Nam, RH; Park, JY, 2015)		2.2
"Finafloxacin is a novel 8-cyano-fluoroquinolone under investigation for treatment of urinary tract infection."( Urinary pharmacokinetics and bactericidal activity of finafloxacin (200 and 800 mg) in healthy volunteers receiving a single oral dose.
Blenk, B; Blenk, H; Dalhoff, A; Naber, KG; Schubert, S; Wagenlehner, CM; Wagenlehner, FM, 2011)		2.06
"Finafloxacin appears to be an acid-pH-favoured antibiotic that may find useful applications in infections where the local pH is low."( Activity of finafloxacin, a novel fluoroquinolone with increased activity at acid pH, towards extracellular and intracellular Staphylococcus aureus, Listeria monocytogenes and Legionella pneumophila.
Lemaire, S; Tulkens, PM; Van Bambeke, F, 2011)		1.47
"Finafloxacin is a new fluoroquinolone antibiotic with the unique property of increasing antibacterial activity at pH values lower than neutral. "( Human pharmacokinetics and safety profile of finafloxacin, a new fluoroquinolone antibiotic, in healthy volunteers.
Andresen, A; Heilmann, HD; Labischinski, H; Lopez-Lazaro, L; Patel, H; Pokorny, R; Seiberling, M; Stubbings, W; Vente, A, 2011)		2.07
"Finafloxacin is a novel fluoroquinolone that exhibits enhanced antibacterial activity under acidic conditions. "( In vitro spectrum of activity of finafloxacin, a novel, pH-activated fluoroquinolone, under standard and acidic conditions.
Endermann, R; Goh, F; Körber-Irrgang, B; Kresken, M; Labischinski, H; Leow, P; Stubbings, W; Yong, GC, 2011)		2.09
"Finafloxacin is a novel fluoroquinolone that exhibits optimal activity at slightly acidic conditions where the activity of other marketed fluoroquinolones decreases."( Comparative in vitro activity of finafloxacin against staphylococci displaying normal and small colony variant phenotypes.
Becker, K; Idelevich, EA; Kahl, BC; Kriegeskorte, A; Peters, G; Stubbings, W, 2011)		1.37

Effects

ExcerptReferenceRelevance
"Finafloxacin has a broad antibacterial spectrum and efficient pharmacokinetic absorption."( Finafloxacin for the treatment of urinary tract infections.
Bartoletti, R; Bjerklund Johansen, TE; Cai, T; M E Wagenlehner, F; Perletti, G, 2015)		2.58

Toxicity

ExcerptReferenceRelevance
" Finafloxacin was safe and well tolerated."( Explorative Randomized Phase II Clinical Study of the Efficacy and Safety of Finafloxacin versus Ciprofloxacin for Treatment of Complicated Urinary Tract Infections.
Bentley, C; Dalhoff, A; Fischer, C; Lückermann, M; Naber, K; Nowicki, M; Vente, A; Wagenlehner, F; Wohlert, S, 2018)		1.62

Pharmacokinetics

The present study assessed the pharmacokinetic properties and the safety and tolerability of finafloxacin following intravenous infusions.

ExcerptReferenceRelevance
" Pharmacokinetic parameters of oral single and multiple doses of up to 800 mg of finafloxacin and safety/tolerability observations were assessed in a phase I study including 95 healthy volunteers."( Human pharmacokinetics and safety profile of finafloxacin, a new fluoroquinolone antibiotic, in healthy volunteers.
Andresen, A; Heilmann, HD; Labischinski, H; Lopez-Lazaro, L; Patel, H; Pokorny, R; Seiberling, M; Stubbings, W; Vente, A, 2011)		0.86
" This review focuses on recent advances concerning quinolones and fluoroquinolones, we will be summarising chemical structure, mode of action, pharmacokinetic properties and toxicity."( Chemical structure and pharmacokinetics of novel quinolone agents represented by avarofloxacin, delafloxacin, finafloxacin, zabofloxacin and nemonoxacin.
Domokos, J; Kocsis, B; Szabo, D, 2016)		0.65
" The present study assessed the pharmacokinetic properties and the safety and tolerability of finafloxacin following intravenous infusions."( Pharmacokinetics of Intravenous Finafloxacin in Healthy Volunteers.
Chiesa, J; Dalhoff, A; Fischer, C; Fuhr, U; Lückermann, M; Taubert, M, 2017)		0.96
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
antimicrobial agentA substance that kills or slows the growth of microorganisms, including bacteria, viruses, fungi and protozoans.
antibacterial drugA drug used to treat or prevent bacterial infections.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (7)

ClassDescription
quinolone
monocarboxylic acidAn oxoacid containing a single carboxy group.
organofluorine compoundAn organofluorine compound is a compound containing at least one carbon-fluorine bond.
secondary amino compoundA compound formally derived from ammonia by replacing two hydrogen atoms by organyl groups.
tertiary amino compoundA compound formally derived from ammonia by replacing three hydrogen atoms by organyl groups.
nitrileA compound having the structure RC#N; thus a C-substituted derivative of hydrocyanic acid, HC#N. In systematic nomenclature, the suffix nitrile denotes the triply bound #N atom, not the carbon atom attached to it.
cyclopropanesCyclopropane and its derivatives formed by substitution.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (136)

Assay IDTitleYearJournalArticle
AID522323Antimicrobial activity against Acinetobacter baumannii isolate 40 harboring GyrA Ser83-Leu mutation at pH 5.82010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522272Antimicrobial activity against Acinetobacter baumannii isolate 57 harboring GyrA Ser83-Leu and ParC Ser80-Phe mutation at pH 7.22010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522240Antimicrobial activity against Acinetobacter baumannii isolate 25 harboring GyrA Ser83-Leu mutation at pH 7.22010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522351Antimicrobial activity against adeB overexpressing Acinetobacter baumannii isolate 68 harboring GyrA Ser83-Leu and ParC Ser80-Leu mutation at pH 5.82010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522304Antimicrobial activity against Acinetobacter baumannii isolate 21 harboring GyrA Ser83-Leu mutation at pH 5.82010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522335Antimicrobial activity against Acinetobacter baumannii isolate 52 harboring GyrA Ser83-Leu and ParC Ser80-Leu mutation at pH 5.82010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522279Antimicrobial activity against Acinetobacter baumannii isolate 64 harboring GyrA Ser83-Leu and ParC Ser80-Leu mutation at pH 7.22010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522280Antimicrobial activity against Acinetobacter baumannii isolate 65 harboring GyrA Ser83-Leu and ParC Ser80-Leu mutation at pH 7.22010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522325Antimicrobial activity against Acinetobacter baumannii isolate 42 harboring GyrA Ser83-Leu mutation at pH 5.82010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522235Antimicrobial activity against Acinetobacter baumannii isolate 20 harboring GyrA Ser83-Leu mutation at pH 7.22010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522247Antimicrobial activity against Acinetobacter baumannii isolate 32 harboring GyrA Ser83-Leu mutation at pH 7.22010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522289Antimicrobial activity against Acinetobacter baumannii isolate 6 at pH 5.82010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522276Antimicrobial activity against Acinetobacter baumannii isolate 61 harboring GyrA Ser83-Leu and ParC Ser80-Leu mutation at pH 7.22010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522295Antimicrobial activity against Acinetobacter baumannii isolate 12 at pH 5.82010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522341Antimicrobial activity against Acinetobacter baumannii isolate 58 harboring GyrA Ser83-Leu and ParC Ser80-Leu mutation at pH 5.82010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522285Antimicrobial activity against Acinetobacter baumannii isolate 2 at pH 5.82010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522296Antimicrobial activity against Acinetobacter baumannii isolate 13 at pH 5.82010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522234Antimicrobial activity against Acinetobacter baumannii isolate 19 harboring GyrA Ser83-Leu mutation at pH 7.22010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522269Antimicrobial activity against Acinetobacter baumannii isolate 54 harboring GyrA Ser83-Leu and ParC Ser80-Leu mutation at pH 7.22010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522321Antimicrobial activity against Acinetobacter baumannii isolate 38 harboring GyrA Ser83-Leu mutation at pH 5.82010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522292Antimicrobial activity against Acinetobacter baumannii isolate 9 at pH 5.82010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522307Antimicrobial activity against Acinetobacter baumannii isolate 24 harboring GyrA Ser83-Leu mutation at pH 5.82010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522262Antimicrobial activity against Acinetobacter baumannii isolate 47 harboring GyrA Ser83-Leu and ParC Ser80-Phe mutation at pH 7.22010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522260Antimicrobial activity against Acinetobacter baumannii isolate 45 harboring GyrA Ser83-Leu and ParC Ser80-Leu mutation at pH 7.22010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522221Antimicrobial activity against Acinetobacter baumannii isolate 6 at pH 7.22010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522239Antimicrobial activity against Acinetobacter baumannii isolate 24 harboring GyrA Ser83-Leu mutation at pH 7.22010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522290Antimicrobial activity against Acinetobacter baumannii isolate 7 at pH 5.82010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522277Antimicrobial activity against Acinetobacter baumannii isolate 62 harboring GyrA Ser83-Leu and ParC Ser80-Leu mutation at pH 7.22010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522330Antimicrobial activity against Acinetobacter baumannii isolate 47 harboring GyrA Ser83-Leu and ParC Ser80-Phe mutation at pH 5.82010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522322Antimicrobial activity against Acinetobacter baumannii isolate 39 harboring GyrA Ser83-Leu mutation at pH 5.82010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522265Antimicrobial activity against Acinetobacter baumannii isolate 50 harboring GyrA Ser83-Leu and ParC Ser80-Leu mutation at pH 7.22010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522310Antimicrobial activity against Acinetobacter baumannii isolate 27 harboring GyrA Ser83-Leu mutation at pH 5.82010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522249Antimicrobial activity against Acinetobacter baumannii isolate 34 harboring GyrA Ser83-Leu mutation at pH 7.22010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522303Antimicrobial activity against Acinetobacter baumannii isolate 20 harboring GyrA Ser83-Leu mutation at pH 5.82010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522241Antimicrobial activity against Acinetobacter baumannii isolate 26 harboring GyrA Ser83-Leu mutation at pH 7.22010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522342Antimicrobial activity against Acinetobacter baumannii isolate 59 harboring GyrA Ser83-Leu and ParC Glu84-Lys mutation at pH 5.82010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522319Antimicrobial activity against Acinetobacter baumannii isolate 36 harboring GyrA Ser83-Leu mutation at pH 5.82010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522336Antimicrobial activity against Acinetobacter baumannii isolate 53 harboring GyrA Ser83-Leu and ParC Ser80-Leu mutation at pH 5.82010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522297Antimicrobial activity against Acinetobacter baumannii isolate 14 at pH 5.82010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522238Antimicrobial activity against Acinetobacter baumannii isolate 23 harboring GyrA Glu87-Gly mutation at pH 7.22010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522267Antimicrobial activity against Acinetobacter baumannii isolate 52 harboring GyrA Ser83-Leu and ParC Ser80-Leu mutation at pH 7.22010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522263Antimicrobial activity against Acinetobacter baumannii isolate 48 harboring GyrA Ser83-Leu and ParC Ser80-Leu mutation at pH 7.22010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522281Antimicrobial activity against Acinetobacter baumannii isolate 66 harboring GyrA Ser83-Leu mutation at pH 7.22010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522282Antimicrobial activity against adeB overexpressing Acinetobacter baumannii isolate 67 harboring GyrA Ser83-Leu and ParC Ser80-Leu mutation at pH 7.22010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522340Antimicrobial activity against Acinetobacter baumannii isolate 57 harboring GyrA Ser83-Leu and ParC Ser80-Phe mutation at pH 5.82010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522220Antimicrobial activity against Acinetobacter baumannii isolate 5 at pH 7.22010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522346Antimicrobial activity against Acinetobacter baumannii isolate 63 harboring GyrA Ser83-Leu and ParC Glu84-Lys mutation at pH 5.82010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522250Antimicrobial activity against Acinetobacter baumannii isolate 35 harboring GyrA Ser83-Leu mutation at pH 7.22010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522332Antimicrobial activity against Acinetobacter baumannii isolate 49 harboring GyrA Ser83-Leu and ParC Ser80-Leu mutation at pH 5.82010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522254Antimicrobial activity against Acinetobacter baumannii isolate 39 harboring GyrA Ser83-Leu mutation at pH 7.22010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522255Antimicrobial activity against Acinetobacter baumannii isolate 40 harboring GyrA Ser83-Leu mutation at pH 7.22010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522253Antimicrobial activity against Acinetobacter baumannii isolate 38 harboring GyrA Ser83-Leu mutation at pH 7.22010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522333Antimicrobial activity against Acinetobacter baumannii isolate 50 harboring GyrA Ser83-Leu and ParC Ser80-Leu mutation at pH 5.82010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522233Antimicrobial activity against Acinetobacter baumannii isolate 18 at pH 7.22010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522242Antimicrobial activity against Acinetobacter baumannii isolate 27 harboring GyrA Ser83-Leu mutation at pH 7.22010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522284Antimicrobial activity against Acinetobacter baumannii isolate 1 at pH 5.82010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522314Antimicrobial activity against Acinetobacter baumannii isolate 31 harboring GyrA Ser83-Leu mutation at pH 5.82010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522274Antimicrobial activity against Acinetobacter baumannii isolate 59 harboring GyrA Ser83-Leu and ParC Glu84-Lys mutation at pH 7.22010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522283Antimicrobial activity against adeB overexpressing Acinetobacter baumannii isolate 68 harboring GyrA Ser83-Leu and ParC Ser80-Leu mutation at pH 7.22010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522337Antimicrobial activity against Acinetobacter baumannii isolate 54 harboring GyrA Ser83-Leu and ParC Ser80-Leu mutation at pH 5.82010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522338Antimicrobial activity against Acinetobacter baumannii isolate 55 harboring GyrA Ser83-Leu and ParC Ser80-Leu mutation at pH 5.82010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522309Antimicrobial activity against Acinetobacter baumannii isolate 26 harboring GyrA Ser83-Leu mutation at pH 5.82010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522298Antimicrobial activity against Acinetobacter baumannii isolate 15 at pH 5.82010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522306Antimicrobial activity against Acinetobacter baumannii isolate 23 harboring GyrA Glu87-Gly mutation at pH 5.82010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522329Antimicrobial activity against Acinetobacter baumannii isolate 46 harboring GyrA Ser83-Leu and ParC Ser80-Leu mutation at pH 5.82010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522291Antimicrobial activity against Acinetobacter baumannii isolate 8 at pH 5.82010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522324Antimicrobial activity against Acinetobacter baumannii isolate 41 harboring GyrA Ser83-Leu mutation at pH 5.82010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522251Antimicrobial activity against Acinetobacter baumannii isolate 36 harboring GyrA Ser83-Leu mutation at pH 7.22010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522225Antimicrobial activity against Acinetobacter baumannii isolate 10 at pH 7.22010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522327Antimicrobial activity against Acinetobacter baumannii isolate 44 harboring GyrA Ser83-Leu and ParC Glu84-Lys mutation at pH 5.82010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522248Antimicrobial activity against Acinetobacter baumannii isolate 33 harboring GyrA Ser83-Leu mutation at pH 7.22010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522244Antimicrobial activity against Acinetobacter baumannii isolate 29 harboring GyrA Ser83-Leu mutation at pH 7.22010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522246Antimicrobial activity against Acinetobacter baumannii isolate 31 harboring GyrA Ser83-Leu mutation at pH 7.22010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522293Antimicrobial activity against Acinetobacter baumannii isolate 10 at pH 5.82010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522305Antimicrobial activity against Acinetobacter baumannii isolate 22 harboring GyrA Ser83-Leu mutation at pH 5.82010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522334Antimicrobial activity against Acinetobacter baumannii isolate 51 harboring GyrA Ser83-Leu and ParC Ser80-Leu mutation at pH 5.82010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522320Antimicrobial activity against Acinetobacter baumannii isolate 37 harboring GyrA Ser83-Leu mutation at pH 5.82010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522287Antimicrobial activity against Acinetobacter baumannii isolate 4 at pH 5.82010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522328Antimicrobial activity against Acinetobacter baumannii isolate 45 harboring GyrA Ser83-Leu and ParC Ser80-Leu mutation at pH 5.82010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522243Antimicrobial activity against Acinetobacter baumannii isolate 28 harboring GyrA Ser83-Leu mutation at pH 7.22010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522315Antimicrobial activity against Acinetobacter baumannii isolate 32 harboring GyrA Ser83-Leu mutation at pH 5.82010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522230Antimicrobial activity against Acinetobacter baumannii isolate 15 at pH 7.22010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522228Antimicrobial activity against Acinetobacter baumannii isolate 13 at pH 7.22010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522245Antimicrobial activity against Acinetobacter baumannii isolate 30 harboring GyrA Ser83-Leu mutation at pH 7.22010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522223Antimicrobial activity against Acinetobacter baumannii isolate 8 at pH 7.22010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522294Antimicrobial activity against Acinetobacter baumannii isolate 11 at pH 5.82010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522300Antimicrobial activity against Acinetobacter baumannii isolate 17 at pH 5.82010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522273Antimicrobial activity against Acinetobacter baumannii isolate 58 harboring GyrA Ser83-Leu and ParC Ser80-Leu mutation at pH 7.22010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522339Antimicrobial activity against Acinetobacter baumannii isolate 56 harboring GyrA Ser83-Leu and ParC Ser80-Leu mutation at pH 5.82010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522257Antimicrobial activity against Acinetobacter baumannii isolate 42 harboring GyrA Ser83-Leu mutation at pH 7.22010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522219Antimicrobial activity against Acinetobacter baumannii isolate 4 at pH 7.22010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522299Antimicrobial activity against Acinetobacter baumannii isolate 16 at pH 5.82010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522288Antimicrobial activity against Acinetobacter baumannii isolate 5 at pH 5.82010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522231Antimicrobial activity against Acinetobacter baumannii isolate 16 at pH 7.22010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522347Antimicrobial activity against Acinetobacter baumannii isolate 64 harboring GyrA Ser83-Leu and ParC Ser80-Leu mutation at pH 5.82010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522514Antimicrobial activity against Acinetobacter baumannii isolate 33 harboring GyrA Ser83-Leu mutation at pH 5.82010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522350Antimicrobial activity against adeB overexpressing Acinetobacter baumannii isolate 67 harboring GyrA Ser83-Leu and ParC Ser80-Leu mutation at pH 5.82010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522278Antimicrobial activity against Acinetobacter baumannii isolate 63 harboring GyrA Ser83-Leu and ParC Glu84-Lys mutation at pH 7.22010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522216Antimicrobial activity against Acinetobacter baumannii isolate 1 at pH 7.22010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522331Antimicrobial activity against Acinetobacter baumannii isolate 48 harboring GyrA Ser83-Leu and ParC Ser80-Leu mutation at pH 5.82010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522258Antimicrobial activity against Acinetobacter baumannii isolate 43 harboring GyrA Ser83-Leu mutation at pH 7.22010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522222Antimicrobial activity against Acinetobacter baumannii isolate 7 at pH 7.22010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522302Antimicrobial activity against Acinetobacter baumannii isolate 19 harboring GyrA Ser83-Leu mutation at pH 5.82010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522270Antimicrobial activity against Acinetobacter baumannii isolate 55 harboring GyrA Ser83-Leu and ParC Ser80-Leu mutation at pH 7.22010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522318Antimicrobial activity against Acinetobacter baumannii isolate 35 harboring GyrA Ser83-Leu mutation at pH 5.82010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522237Antimicrobial activity against Acinetobacter baumannii isolate 22 harboring GyrA Ser83-Leu mutation at pH 7.22010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522343Antimicrobial activity against Acinetobacter baumannii isolate 60 harboring GyrA Ser83-Leu and ParC Ser80-Phe mutation at pH 5.82010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522345Antimicrobial activity against Acinetobacter baumannii isolate 62 harboring GyrA Ser83-Leu and ParC Ser80-Leu mutation at pH 5.82010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522227Antimicrobial activity against Acinetobacter baumannii isolate 12 at pH 7.22010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522275Antimicrobial activity against Acinetobacter baumannii isolate 60 harboring GyrA Ser83-Leu and ParC Ser80-Leu mutation at pH 7.22010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522256Antimicrobial activity against Acinetobacter baumannii isolate 41 harboring GyrA Ser83-Leu mutation at pH 7.22010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522317Antimicrobial activity against Acinetobacter baumannii isolate 34 harboring GyrA Ser83-Leu mutation at pH 5.82010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522236Antimicrobial activity against Acinetobacter baumannii isolate 21 harboring GyrA Ser83-Leu mutation at pH 7.22010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522266Antimicrobial activity against Acinetobacter baumannii isolate 51 harboring GyrA Ser83-Leu and ParC Ser80-Leu mutation at pH 7.22010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522226Antimicrobial activity against Acinetobacter baumannii isolate 11 at pH 7.22010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522348Antimicrobial activity against Acinetobacter baumannii isolate 65 harboring GyrA Ser83-Leu and ParC Ser80-Leu mutation at pH 5.82010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522301Antimicrobial activity against Acinetobacter baumannii isolate 18 at pH 5.82010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522232Antimicrobial activity against Acinetobacter baumannii isolate 17 at pH 7.22010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522218Antimicrobial activity against Acinetobacter baumannii isolate 3 at pH 7.22010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522311Antimicrobial activity against Acinetobacter baumannii isolate 28 harboring GyrA Ser83-Leu mutation at pH 5.82010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522261Antimicrobial activity against Acinetobacter baumannii isolate 46 harboring GyrA Ser83-Leu and ParC Ser80-Leu mutation at pH 7.22010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522445Antimicrobial activity against Acinetobacter baumannii isolate 37 harboring GyrA Ser83-Leu mutation at pH 7.22010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522308Antimicrobial activity against Acinetobacter baumannii isolate 25 harboring GyrA Ser83-Leu mutation at pH 5.82010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522286Antimicrobial activity against Acinetobacter baumannii isolate 3 at pH 5.82010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522217Antimicrobial activity against Acinetobacter baumannii isolate 2 at pH 7.22010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522268Antimicrobial activity against Acinetobacter baumannii isolate 53 harboring GyrA Ser83-Leu and ParC Ser80-Leu mutation at pH 7.22010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522271Antimicrobial activity against Acinetobacter baumannii isolate 56 harboring GyrA Ser83-Leu and ParC Ser80-Leu mutation at pH 7.22010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522264Antimicrobial activity against Acinetobacter baumannii isolate 49 harboring GyrA Ser83-Leu and ParC Ser80-Leu mutation at pH 7.22010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522344Antimicrobial activity against Acinetobacter baumannii isolate 61 harboring GyrA Ser83-Leu and ParC Ser80-Leu mutation at pH 5.82010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522313Antimicrobial activity against Acinetobacter baumannii isolate 30 harboring GyrA Ser83-Leu mutation at pH 5.82010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522229Antimicrobial activity against Acinetobacter baumannii isolate 14 at pH 7.22010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522259Antimicrobial activity against Acinetobacter baumannii isolate 44 harboring GyrA Ser83-Leu and ParC Glu84-Lys mutation at pH 7.22010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522326Antimicrobial activity against Acinetobacter baumannii isolate 43 harboring GyrA Ser83-Leu mutation at pH 5.82010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522349Antimicrobial activity against Acinetobacter baumannii isolate 66 harboring GyrA Ser83-Leu mutation at pH 5.82010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522224Antimicrobial activity against Acinetobacter baumannii isolate 9 at pH 7.22010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
AID522312Antimicrobial activity against Acinetobacter baumannii isolate 29 harboring GyrA Ser83-Leu mutation at pH 5.82010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (16)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's15 (93.75)24.3611
2020's1 (6.25)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 35.40

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index35.40 (24.57)
Research Supply Index3.04 (2.92)
Research Growth Index6.03 (4.65)
Search Engine Demand Index44.85 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (35.40)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (25.00%)5.53%
Reviews3 (18.75%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (56.25%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (7)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Double-Blind, Double-Dummy, Prospective, Randomized Multiple-Site Study of Oral Finafloxacin 300 mg b.i.d. Versus Oral Ciprofloxacin 250 mg b.i.d. in Patients With Lower Uncomplicated UTI (uUTI) With a Treatment Duration of 3 Days [NCT00722735]Phase 236 participants (Anticipated)Interventional2008-10-31Completed
Finafloxacin - A Double-blind, Placebo-controlled, Randomised, Dose-escalating, Crossover Study to Determine the Safety and Tolerability of Single and Multiple Intravenous Doses of Finafloxacin in Healthy Subjects [NCT01910883]Phase 158 participants (Actual)Interventional2010-09-30Completed
An Open-Label Study to Assess the Safety, Tolerability, and Pharmacokinetic Profile in Plasma and Epithelial Lining Fluid of Finafloxacin After Single and Multiple Doses Administered Orally in Healthy Volunteers [NCT01907867]Phase 118 participants (Actual)Interventional2012-01-31Completed
Determination of the Effect of Age and Gender on the Pharmacokinetics and Tolerability of a Single Dose of Finafloxacin-HCL in Healthy Volunteers [NCT01904162]Phase 140 participants (Actual)Interventional2010-02-28Completed
An Open-Label, Randomized, Multicenter, Two-Arms Efficacy and Safety Study of 14 Days Treatment With Finafloxacin 400 mg b.i.d. Plus Amoxicillin 1000 mg b.i.d.Versus Finafloxacin 400 mg b.i.d. Plus Esomeprazole 40 mg b.i.d. in Patients With Helicobacter P [NCT00723502]Phase 230 participants (Anticipated)Interventional2008-09-30Completed
A Double-Blind, Placebo-Controlled, Randomized, Dose-Escalating Study of Single and Multiple Oral Doses of Finafloxacin Hydrochloride in Healthy Subjects and a Study of H. Pylori Treatment in Healthy Carriers [NCT00483158]Phase 195 participants (Actual)Interventional2007-08-31Completed
A Multi-Dose, Double-Blind, Double-Dummy, Active- Control, Randomized Clinical (Phase II) Study of Two Dosing Regimens of Finafloxacin for the Treatment of cUTI and/or Acute Pyelonephritis Requiring Hospitalisation. [NCT01928433]Phase 2225 participants (Actual)Interventional2012-12-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT01928433 (6) [back to overview]Number of Participants With Clinical and Microbiological Response
NCT01928433 (6) [back to overview]Number of Participants With Clinical and Microbiological Response at the End of Study (EoS) Visit (Day 24).
NCT01928433 (6) [back to overview]Number of Participants With Clinical and Microbiological Response at the End of Therapy (EoT) Visit (Day 10).
NCT01928433 (6) [back to overview]Number of Participants With Clinical and Microbiological Response at the On Therapy (OT) Visit (Day 3).
NCT01928433 (6) [back to overview]The Safety and Tolerability of Multiple Doses of Finafloxacin: Number of Participants Who Discontinued Due to TEAE
NCT01928433 (6) [back to overview]The Safety and Tolerability of Multiple Doses of Finafloxacin: Number of Treatment-emergent Adverse Events

Number of Participants With Clinical and Microbiological Response

"The primary endpoint of this study is the clinical and microbiological response of patients with cUTI or pyelonephritis to treatment with finafloxacin for 5 days versus finafloxacin for 10 days versus ciprofloxacin for 10 days as a reference comparator at the Test of Cure (ToC) visit (Day 17) in the microbiological intent-to-treat population (micro-ITT population).~Clinical response is defined as resolution of the symptoms of cUTI present at trial entry and no new symptoms developed. Microbiological response is defined as elimination or reduction of study entry pathogens to ≤ 10e3 CFU/mL on urine culture. The clinical and microbiological response will be assessed for each group on Day 17 and will be compared between the three groups to assess the efficacy in each group." (NCT01928433)
Timeframe: Day 17

InterventionParticipants (Count of Participants)
Finafloxacin 5 Days45
Finafloxacin 10 Days46
Ciprofloxacin 10 Days35

[back to top]

Number of Participants With Clinical and Microbiological Response at the End of Study (EoS) Visit (Day 24).

The clinical and microbiological response as the efficacy parameter will be assessed for each group and will be compared between the three groups. Separate analyses will be performed for all time points for the clinical and microbiological responders and compared also between the different groups. (NCT01928433)
Timeframe: Day 24

InterventionParticipants (Count of Participants)
Finafloxacin 5 Days47
Finafloxacin 10 Days42
Ciprofloxacin 10 Days34

[back to top]

Number of Participants With Clinical and Microbiological Response at the End of Therapy (EoT) Visit (Day 10).

The clinical and microbiological response as the efficacy parameter will be assessed for each group and will be compared between the three groups. Separate analyses will be performed for all time points for the clinical and microbiological responders and compared also between the different groups. (NCT01928433)
Timeframe: Day 10

InterventionParticipants (Count of Participants)
Finafloxacin 5 Days49
Finafloxacin 10 Days49
Ciprofloxacin 10 Days44

[back to top]

Number of Participants With Clinical and Microbiological Response at the On Therapy (OT) Visit (Day 3).

The clinical and microbiological response as the efficacy parameter will be assessed for each group and will be compared between the three groups. Separate analyses will be performed for all time points for the clinical and microbiological responders and compared also between the different groups. (NCT01928433)
Timeframe: Day 3

InterventionParticipants (Count of Participants)
Finafloxacin 5 Days39
Finafloxacin 10 Days40
Ciprofloxacin 10 Days33

[back to top]

The Safety and Tolerability of Multiple Doses of Finafloxacin: Number of Participants Who Discontinued Due to TEAE

This study will evaluate the safety of the different regimens of finafloxacin. The safety outcome measures assessed are the following: vital signs, physical examinations, ECGs, haematology, biochemistry, urinalysis, adverse events and serious adverse events. Adverse events and serious adverse events will be documented throughout the study for each group (including comparator group and the incidence and severity of their occurrence will be compared between all groups. The results of all other safety outcome measures will be compared with the baseline values of each group to determine if significant changes occurred during the course of the study within one group. The results at the different visits will also be compared between the groups to identify significant differences between the 3 treatment groups. (NCT01928433)
Timeframe: Screening to day 24

InterventionParticipants (Count of Participants)
Finafloxacin 5 Days7
Finafloxacin 10 Days2
Ciprofloxacin 10 Days4

[back to top]

The Safety and Tolerability of Multiple Doses of Finafloxacin: Number of Treatment-emergent Adverse Events

This study will evaluate the safety of the different regimens of finafloxacin. The safety outcome measures assessed are the following: vital signs, physical examinations, ECGs, haematology, biochemistry, urinalysis, adverse events and serious adverse events. Adverse events and serious adverse events will be documented throughout the study for each group (including comparator group and the incidence and severity of their occurrence will be compared between all groups. The results of all other safety outcome measures will be compared with the baseline values of each group to determine if significant changes occurred during the course of the study within one group. The results at the different visits will also be compared between the groups to identify significant differences between the 3 treatment groups. (NCT01928433)
Timeframe: Screening to Day 24

InterventionTreatment-emergent AEs (Number)
Finafloxacin 5 Days70
Finafloxacin 10 Days51
Ciprofloxacin 10 Days70

[back to top]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
ciprofloxacin
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.. ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.		5.4951aminoquinoline;
cyclopropanes;
fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone;
zwitterion		antibacterial drug;
antiinfective agent;
antimicrobial agent;
DNA synthesis inhibitor;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
environmental contaminant;
topoisomerase IV inhibitor;
xenobiotic
ofloxacin
Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.. 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.. ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.		2.06103-oxo monocarboxylic acid;
N-arylpiperazine;
N-methylpiperazine;
organofluorine compound;
oxazinoquinoline
aspartic acid
Aspartic Acid: One of the non-essential amino acids commonly occurring in the L-form. It is found in animals and plants, especially in sugar cane and sugar beets. It may be a neurotransmitter.. aspartic acid : An alpha-amino acid that consists of succinic acid bearing a single alpha-amino substituent. L-aspartic acid : The L-enantiomer of aspartic acid.		2.1110aspartate family amino acid;
aspartic acid;
L-alpha-amino acid;
proteinogenic amino acid		Escherichia coli metabolite;
mouse metabolite;
neurotransmitter
carbostyril
Quinolones: A group of derivatives of naphthyridine carboxylic acid, quinoline carboxylic acid, or NALIDIXIC ACID.. quinolin-2(1H)-one : A quinolone that is 1,2-dihydroquinoline substituted by an oxo group at position 2.		3.2310monohydroxyquinoline;
quinolone		bacterial xenobiotic metabolite
asparagine
Asparagine: A non-essential amino acid that is involved in the metabolic control of cell functions in nerve and brain tissue. It is biosynthesized from ASPARTIC ACID and AMMONIA by asparagine synthetase. (From Concise Encyclopedia Biochemistry and Molecular Biology, 3rd ed). asparagine : An alpha-amino acid in which one of the hydrogens attached to the alpha-carbon of glycine is substituted by a 2-amino-2-oxoethyl group.		2.1110amino acid zwitterion;
asparagine;
aspartate family amino acid;
L-alpha-amino acid;
proteinogenic amino acid		Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite
imipenem, anhydrous
Imipenem: Semisynthetic thienamycin that has a wide spectrum of antibacterial activity against gram-negative and gram-positive aerobic and anaerobic bacteria, including many multiresistant strains. It is stable to beta-lactamases. Clinical studies have demonstrated high efficacy in the treatment of infections of various body systems. Its effectiveness is enhanced when it is administered in combination with CILASTATIN, a renal dipeptidase inhibitor.. imipenem : A broad-spectrum, intravenous beta-lactam antibiotic of the carbapenem subgroup.		2.2510beta-lactam antibiotic allergen;
carbapenems;
zwitterion		antibacterial drug
levofloxacin
Levofloxacin: The L-isomer of Ofloxacin.. levofloxacin : An optically active form of ofloxacin having (S)-configuration; an inhibitor of bacterial topoisomerase IV and DNA gyrase.		7.85309-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid;
fluoroquinolone antibiotic;
quinolone antibiotic		antibacterial drug;
DNA synthesis inhibitor;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
topoisomerase IV inhibitor
moxifloxacin
Moxifloxacin: A fluoroquinolone that acts as an inhibitor of DNA TOPOISOMERASE II and is used as a broad-spectrum antibacterial agent.. moxifloxacin : A quinolone that consists of 4-oxo-1,4-dihydroquinoline-3-carboxylic acid bearing a cyclopropyl substituent at position 1, a fluoro substitiuent at position 6, a (4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl group at position 7 and a methoxy substituent at position 8. A member of the fluoroquinolone class of antibacterial agents.		2.1110aromatic ether;
cyclopropanes;
fluoroquinolone antibiotic;
pyrrolidinopiperidine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone		antibacterial drug
abt 492
WQ 3034: structure in first source		3.2310
zabofloxacin
zabofloxacin: a fluoroquinolone antibiotic		8.2310
nemonoxacin
nemonoxacin: has antibacterial activity		8.2310quinolines
ConditionIndicatedRelationship StrengthStudiesTrials
Acinetobacter Infections
Infections with bacteria of the genus ACINETOBACTER.		02.0510
Necrotizing Pyelonephritis
[description not available]		04.4811
Pyelonephritis
Inflammation of the KIDNEY involving the renal parenchyma (the NEPHRONS); KIDNEY PELVIS; and KIDNEY CALICES. It is characterized by ABDOMINAL PAIN; FEVER; NAUSEA; VOMITING; and occasionally DIARRHEA.		16.4811
Urinary Tract Infections
Inflammatory responses of the epithelium of the URINARY TRACT to microbial invasions. They are often bacterial infections with associated BACTERIURIA and PYURIA.		18.7441
External Ear Inflammation
[description not available]		03.0310
Otitis Externa
Inflammation of the OUTER EAR including the external EAR CANAL, cartilages of the auricle (EAR CARTILAGE), and the TYMPANIC MEMBRANE.		15.0310
Infections, Helicobacter
[description not available]		02.1110
Helicobacter Infections
Infections with organisms of the genus HELICOBACTER, particularly, in humans, HELICOBACTER PYLORI. The clinical manifestations are focused in the stomach, usually the gastric mucosa and antrum, and the upper duodenum. This infection plays a major role in the pathogenesis of type B gastritis and peptic ulcer disease.		02.1110
Infections, Staphylococcal
[description not available]		02.0610
Staphylococcal Infections
Infections with bacteria of the genus STAPHYLOCOCCUS.		02.0610